Vertex Pharmaceuticals Aktie News

SHANGHAI, Feb. 2, 2026 /PRNewswire/ -- WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) for an innovative trispecific T-cell Engager (TCE) for the treatment of B-cell mediated autoimmune diseases.

Vertex Pharmaceuticals could have several important catalysts this year. The stock's long-term outlook seems highly attractive.

GreensKeeper Value Fund Q4 2025 Portfolio Update: Long-Term Winners

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex ...

This "forever" portfolio includes two "Magnificent Seven" stocks that should remain magnificent. It features a conglomerate that's preserving its long-time leader's legacy.

These players each are leaders in their specialty areas and have generated billions of dollars in revenue. This list includes a biotech stock, a pharma player, and a medical device company.

Vertex Pharmaceuticals Incorporated (VRTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT. “2025 was a year of strong commercial execution and rapid R&D progress, ...